title: Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165.
abstract: Bleeding episodes and other side effects may complicate the treatment with oral anticoagulants. We report on the results of 66 patients who were treated with a low molecular weight heparin fraction for up to 19 months. The data of the study demonstrate the effective long-term anticoagulation with low-molecular-weight heparin and the reduced incidence of hemorrhages compared with conventional anticoagulants. Thus, low-molecular-weight heparin may be effectively and safely used for long-term anticoagulation in patients with bleeding problems on conventional anticoagulants.
authors.affiliation: Medical Clinic I, Klinikum Mannheim, University of Heidelberg, FRG.
authors.forename: J
authors.initials: J
authors.lastname: Harenberg
authors.forename: G
authors.initials: G
authors.lastname: Leber
authors.forename: R
authors.initials: R
authors.lastname: Raedsch
authors.forename: R
authors.initials: R
authors.lastname: Zimmermann
authors.forename: F
authors.initials: F
authors.lastname: Schwarz
authors.forename: W
authors.initials: W
authors.lastname: Kübler
mesh_terms: D002986:Clinical Trials as Topic; D015951:Factor Xa; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D015842:Serine Proteinase Inhibitors; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D015842:Serine Proteinase Inhibitors; D015951:Factor Xa